Unknown

Dataset Information

0

Reverse-engineering the anti-MUC1 antibody 139H2 by mass spectrometry-based de novo sequencing.

ABSTRACT: Mucin 1 (MUC1) is a transmembrane mucin expressed at the apical surface of epithelial cells at mucosal surfaces. MUC1 has a barrier function against bacterial invasion and is well known for its aberrant expression and glycosylation in adenocarcinomas. The MUC1 extracellular domain contains a variable number of tandem repeats (VNTR) of 20 amino acids, which are heavily O-linked glycosylated. Monoclonal antibodies against the MUC1 VNTR are powerful research tools with applications in the diagnosis and treatment of MUC1-expressing cancers. Here, we report direct mass spectrometry-based sequencing of anti-MUC1 hybridoma-derived 139H2 IgG, enabling reverse-engineering of the functional recombinant monoclonal antibody. The crystal structure of the 139H2 Fab fragment in complex with the MUC1 epitope was solved, revealing the molecular basis of 139H2 binding specificity to MUC1 and its tolerance to O-glycosylation of the VNTR. The available sequence of 139H2 will allow further development of MUC1-related diagnostic, targeting, and treatment strategies.

SUBMITTER: Peng W 

PROVIDER: S-EPMC10955041 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Reverse-engineering the anti-MUC1 antibody 139H2 by mass spectrometry-based de novo sequencing.

Peng Weiwei W   Giesbers Koen Cap KC   Šiborová Marta M   Beugelink J Wouter JW   Pronker Matti F MF   Schulte Douwe D   Hilkens John J   Janssen Bert Jc BJ   Strijbis Karin K   Snijder Joost J  

Life science alliance 20240320 6

Mucin 1 (MUC1) is a transmembrane mucin expressed at the apical surface of epithelial cells at mucosal surfaces. MUC1 has a barrier function against bacterial invasion and is well known for its aberrant expression and glycosylation in adenocarcinomas. The MUC1 extracellular domain contains a variable number of tandem repeats (VNTR) of 20 amino acids, which are heavily <i>O</i>-linked glycosylated. Monoclonal antibodies against the MUC1 VNTR are powerful research tools with applications in the di  ...[more]

Similar Datasets

Unknown Resurrection of a clinical antibody: template proteogenomic de novo proteomic sequencing and reverse engineering of an anti-lymphotoxin-α antibody.
| S-EPMC3253889 | biostudies-literature
Unknown Lessons in de novo peptide sequencing by tandem mass spectrometry.
| S-EPMC4367481 | biostudies-literature
Proteomics Sequencing the anti-MUC1 hybridoma antibody 139H2
2024-03-18 | PXD043489 | Pride
Unknown Constrained De Novo Sequencing of neo-Epitope Peptides using Tandem Mass Spectrometry.
| S-EPMC6901291 | biostudies-literature
Unknown A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies.
| S-EPMC9225641 | biostudies-literature
Unknown Combining phage display with de novo protein sequencing for reverse engineering of monoclonal antibodies.
| S-EPMC4966834 | biostudies-literature
Unknown Multienzyme deep learning models improve peptide de novo sequencing by mass spectrometry proteomics.
| S-EPMC9891523 | biostudies-literature
Unknown A high-throughput de novo sequencing approach for shotgun proteomics using high-resolution tandem mass spectrometry.
| S-EPMC2838866 | biostudies-other
Unknown Mass Spectrometry-Based Direct Sequencing of tRNAs De Novo and Quantitative Mapping of Multiple RNA Modifications.
| S-EPMC11421004 | biostudies-literature
Unknown PowerNovo: de novo peptide sequencing via tandem mass spectrometry using an ensemble of transformer and BERT models.
| S-EPMC11217302 | biostudies-literature